A five-membered heterocyclic-fused heterocycloalkyl compound, a pharmaceutical composition containing the same and applications
By developing highly selective and active JAK3 kinase inhibitors, five-membered heterocyclic fused heterocyclic alkyl compounds, the problems of insufficient selectivity and significant side effects of existing JAK inhibitors have been solved, achieving effective treatment for diseases with abnormal JAK-STAT signaling pathways.
CN118084939BActive Publication Date: 2026-06-05HANG ZHOU YUHONG PHARMATECH CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HANG ZHOU YUHONG PHARMATECH CO LTD
- Filing Date
- 2022-08-24
- Publication Date
- 2026-06-05
Smart Images
Figure CN118084939B_ABST
Abstract
The application belongs to the technical field of medicine, and discloses a kind of five-membered heterocyclic ring condensation heterocyclic alkyl compound, pharmaceutical composition containing it and application.Five-membered heterocyclic ring condensation heterocyclic alkyl compound is the compound of structure shown in general formula III-1, III-3 or III-4, optical isomer thereof, deuterium compound thereof or its pharmaceutically acceptable salt, structural formula of compound shown in formula III-1, III-3 or III-4 as follows, wherein X, Y, L, W and R7 are as defined herein.The compound disclosed in the application can be used for treating diseases related to JAK3 kinase overactivation or overexpression, such as autoimmune diseases, lung injury, organ transplant rejection diseases.In vitro experiments show that the series of compounds have good JAK3 kinase inhibition activity, and have good application prospect in the field of medicine.
Need to check novelty before this filing date? Find Prior Art